Journey Medical Corporation (DERM)
$2.815
Rating:
Recommendation:
Buy
| Symbol | DERM |
|---|---|
| Price | $2.815 |
| Beta | 0.000 |
| Volume Avg. | 0.15M |
| Market Cap | 51.047M |
| Shares () | - |
| 52 Week Range | 1.02-3.19 |
| 1y Target Est | - |
| DCF Unlevered | DERM DCF -> | |
|---|---|---|
| DCF Levered | DERM LDCF -> | |
| ROE | -309.07% | Strong Sell |
| ROA | -56.13% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 201920.00% | Strong Buy |
| P/E | -1.25 | Sell |
| P/B | 10,136.85 | Strong Buy |
Latest DERM news
About
Download (Excel)Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.